INMD — Inmode Ltd
NASDAQ · Health Care · Health Care
- Latest Close
- $14.51
- 30-Day Move
- +0.4%
- Market Cap
- $874M
- Shares Outstanding
- 63,360,000
- P/E Ratio
- 9.31
- P/B Ratio
- 1.36
Analyst consensus: Buy · 13 analysts
Inmode Ltd
A read-only Alphactor snapshot forInmode Ltd. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$14.51
30-Day Move
+0.4%
Market Cap
$874M
Shares Outstanding
63,360,000
P/E Ratio
9.31
P/B Ratio
1.36
$14.51
+0.4%last 90 delayed daily bars
90D High
$16.67
90D Low
$12.72
Avg Volume
971,333
Gross margin is running at 78.5%, which gives a quick read on operating quality before you open the full model.
Net margin is 25.3%, useful for comparing INMD against peers in Health Care.
INMD is up 0.4% over the last 30 trading days shown on this page.
Latest operating income is $26M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$23.88
Rule of 40
16.6%
Dark Pool Short %
45.8%
Latest Close
$14.51
30-Day Move
+0.4%
Market Cap
$874M
Shares Outstanding
63,360,000
P/E Ratio
9.31
P/B Ratio
1.36
ROE
13.7%
ROA
12.2%
Gross Margin
78.5%
Operating Margin
23.1%
Net Margin
25.3%
Debt / Equity
0
Current Ratio
9.88
Latest Revenue
$104M
Revenue
$104M
Gross Profit
$81M
Operating Income
$26M
Net Income
$27M
Gross Margin
7854.0%
Net Margin
2533.0%
Current Ratio
9.88
Debt / Equity
0.00
Fair Value
$23.88
Upside / Downside
+64.6%
Signal
Undervalued
Implied Growth
-7.5%
DCF
$16.89
EPV
$20.87
EV/Rev
$33.88
Growth Assumption
-6.6%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
$84M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
9.90
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.91x
Rule of 40
16.6%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $454M | $198M | $162M | $180M |
| 2023-12-31 | $492M | $196M | $198M | $176M |
| 2024-12-31 | $395M | $113M | $181M | $132M |
| 2025-12-31 | $370M | $85M | $94M | $84M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| JANUS INVESTMENT FUND-Janus Henderson Small Cap Value Fund | 887,471 | 0.01% | 2025-12-31 |
| iShares Trust-iShares Core MSCI EAFE ETF | 517,633 | 0.01% | 2026-02-28 |
| Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund | 376,215 | 0.01% | 2026-01-31 |
| JPMorgan Trust I-JPMorgan Small Cap Blend Fund | 334,875 | 0.01% | 2025-12-31 |
| HOTCHKIS & WILEY Fd.S/DE/-Hotchkis & Wiley Small Cap Diversified Value | 225,400 | 0.00% | 2025-12-31 |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 228,620 | 0.00% | 2026-02-28 |
| iShares Trust-iShares Core MSCI Total International Stock ETF | 187,508 | 0.00% | 2026-02-28 |
| ARK ETF Trust-ARK Israel Innovative Technology ETF | 157,726 | 0.00% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-05-15
--
--
Invesco
Filed 2026-02-19
--
--
BlackRock
Filed 2024-05-10
$135M
--
Renaissance Technologies
Filed 2025-05-14
$41M
--
Goldman Sachs
Filed 2026-02-10
$21M
+48.9%
Vanguard Group
Filed 2025-05-09
$11M
-16.0%
Northern Trust
Filed 2025-05-13
$11M
-8.8%
Citadel Advisors
Filed 2025-11-14
$9M
--
3.77
Consensus
Buy—
—
—
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.